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OBJECTIVES: Forkhead box P3 (FoxP3) expression has been observed in human cancer cells but has not yet been
reported in thyroid cells. We investigated the prognostic significance of both FoxP3 expression and intratumoral
FoxP3
+ lymphocyte infiltration in differentiated thyroid carcinoma cells.
METHODS: We constructed a tissue microarray with 385 thyroid tissues, including 266 malignant tissues (from 253
papillary thyroid carcinomas and 13 follicular carcinomas), 114 benign lesions, and 5 normal thyroid tissues.
RESULTS: We determined the expression of FoxP3 in both tumor cells and tumor-infiltrating lymphocytes using
immunohistochemical techniques. Cellular expression of FoxP3 was evident in 71% of benign and 91.9% of
malignant tissues. The nuclear and cytoplasmic expression patterns were quantified separately. A multivariate
logistic regression analysis indicated that cytoplasmic FoxP3 expression is an independent risk factor for thyroid
malignancy. Cytoplasmic FoxP3 staining was inversely correlated with patient age. Nuclear FoxP3 staining was more
intense in younger patients and in tumors presenting with metastasis at diagnosis. FoxP3
+ lymphocytes were more
frequent in tumors smaller than 2 cm, those without extrathyroidal invasion, and in patients with concurrent
chronic lymphocytic thyroiditis.
CONCLUSIONS: We demonstrated FoxP3 expression in differentiated thyroid carcinoma cells and found evidence
that this expression may exert an important influence on several features of tumor aggressiveness.
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INTRODUCTION
Forkhead box P3 (FoxP3) is a member of the forkhead/
winged-helix family of transcriptional regulators, which are
involved in immune system development and function,
notably in the generation of immunosuppressive regulatory
T cells (Tregs) (1). The loss of FoxP3 function leads to a
reduction in the number of Tregs, resulting in lethal
autoaggressive lymphoproliferation, whereas the overex-
pression of FoxP3 causes severe immunodeficiency (2).
Because FoxP3 helps to specify Treg lineages, its expression
in primarily lymphoid tissues is expected and has been well
documented (3,4). In addition, FoxP3 expression has been
observed in human cancer cells, but has not yet been
described in thyroid tumors (5).
There is increasing evidence that Tregs also play an
important role in cancer immune evasion, which enables
tumor cells to elude the host antitumor immune response (6-
8). However, the contribution of Tregs to tumor progression
and their clinical significance remain poorly understood.
Some studies have suggested that the presence of Tregs
indicates a worse prognosis (9-11), whereas others have
associated their presence with favorable outcomes (12,13). A
recent meta-analysis concluded that Treg lymphocytic
infiltration was not sufficient to either improve or worsen
the prognosis of cancer patients (14).
The existence of an immune response against differen-
tiated thyroid carcinomas has long been recognized (15-17).
Previous research has suggested that a local inflammatory
response may impede tumor evolution (18) and may indicate
a more favorable outcome (15,16). However, a recent study
found an association between the presence of Tregs and
lymph node metastasis in papillary thyroid carcinomas (19).
Unfortunately, the authors did not evaluate the expression of
FoxP3 in the analyzed tumor cells.
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483In this work, we investigated the expression of FoxP3 in
malignant and benign thyroid cells. Furthermore, we
explored the clinical and pathological roles and the prog-
nosticsignificanceofbothFoxP3expressionandintratumoral
Treg infiltration in differentiated thyroid carcinomas.
MATERIALS AND METHODS
Patients
We investigated 380 patients, from whom tissue samples
were removed and maintained in the tissue bank of the A.
C. Camargo Hospital, as summarized in Table 1. Thyroid
carcinoma was diagnosed in 266 patients: 253 had papillary
thyroid carcinoma (PTC; 153 cases of the classical form, 80
follicular variants and 20 tall cell variants), and 13 had
follicular carcinomas (seven minimally invasive and six
frankly invasive). In addition, we obtained samples from
five normal thyroid tissues and 114 benign thyroid lesions,
including 58 nodular goiters and 56 follicular adenomas.
Clinical information was obtained from the patients’ files.
The tumor aggressiveness at diagnosis was ascertained using
the Tumor Node Metastasis classification systemand the stage
classification system for differentiated thyroid carcinomas
(20). The patients were followed according to a standard
protocol that included periodic total body scans, serum TSH
and thyroglobulin (Tg) measurements, X-rays, ultrasonogra-
phy, computed tomography scans and other procedures as
required to detect distant metastases for 12-298 months (mean
43.50¡33.29 months; Mo=21 months). Patients presenting
with high non-stimulated serum Tg levels (.2m g / d l )w e r e
subjected to a thorough imaging scan. We used the aforemen-
tioned parameters to define tumors as persistent/recurrent
and/or presenting with distant metastasis.
Formalin-fixed, paraffin-embedded tissues from all 380
cases were reviewed for diagnostic confirmation and to
select the most representative areas for the construction of a
tissue microarray (Beecher InstrumentsH, Silver Springs,
MD, USA) for immunohistochemical analysis.
Chronic lymphocytic thyroiditis was investigated in the
nonmalignant thyroid parenchyma of the tumor contral-
ateral lobe and was characterized by extensive lymphocytic
infiltration with lymphoid follicles, scarring and follicular
regenerative activity evidenced by numerous small follicles,
which were frequently lined by Hurthle cells (21). The
clinical diagnosis of Hashimoto’s thyroiditis was confirmed
with patient serum thyroperoxidase and thyroglobulin
antibody titers.
Immunohistochemistry
The 5-mm tissue sections intended for microarray con-
struction were placed on electrically charged slides, depar-
affinized, and rehydrated with alcohol solutions of
decreasing concentration. The endogenous peroxide activity
was blocked with H2O2 for 15 min. All the tissue sections
were subjected to heat-induced antigen retrieval using a
10% citrate buffer (10 mM, pH 6.0) in a steamer (90˚C for
30 min). The tissue sections were then incubated overnight
at 6˚C with a 1:500 anti-FoxP3 mouse monoclonal antibody
(clone 236A/E7; Abcam, Cambridge, UK). The Advance
(DAKO, Carpenteria, CA, USA) was used as the reaction
detection system. DAB (3.3-diaminobenzidine-tetrahy-
drochloride; Sigma, St. Louis, MA, USA) was applied as a
chromogen for 5 min at room temperature, and the sections
were counterstained with hematoxylin. Positive and nega-
tive controls were assayed in the same batch of reactions as
the patient samples.
Immunohistochemical evaluation
The slides were scored independently by two pathologists
(JV and FAS), both of whom were blinded to the tumor
Table 1 - FoxP3 immunostaining and FoxP3
+ lymphocytic infiltration in different thyroid tissue subsets.
Analyzed Groups Statistical Parameters Cytoplasmic FoxP3* Nuclear FoxP3* FoxP3
+ Lymphocytes
Malignant vs. Benign Accuracy (%) 61.89 50.86 38.89
Sensitivity (%) 62.10 50.20 11.79
Specificity (%) 61.40 52.50 100.00
PPV (%) 79.04 72.61 100.00
NPV (%) 40.86 29.59 33.45
p-value 0.0005 0.1514 0.0001
PTC vs. FTC Accuracy (%) 59.49 53.71 69.34
Sensitivity (%) 72.20 59.50 0.00
Specificity (%) 56.60 52.40 85.47
PPV (%) 27.41 21.99 0.00
NPV (%) 89.97 85.16 78.61
p-value 0.0143 0.5937 0.0055
FA vs. FVPTC Accuracy (%) 55.69 57.41 54.72
Sensitivity (%) 45.70 67.30 5.88
Specificity (%) 64.70 48.10 100.00
PPV (%) 53.85 54.98 100.00
NPV (%) 56.94 60.97 53.40
p-value 0.6885 0.1864 0.1079
FA vs. FC Accuracy (%) 55.17 57.34 57.89
Sensitivity (%) 63.90 70.30 0.00
Specificity (%) 49.00 48.10 100.00
PPV (%) 46.95 49.11 50.00
NPV (%) 65.77 69.45 57.89
P-value 0.6760 0.1735 n.e.
Abbreviations: FA= follicular adenoma; PTC=papillary thyroid carcinoma; FVPTC= follicular variant of papillary thyroid carcinoma; FC=follicular
carcinoma; PPV=positive predictive value; NPV=negative predictive value; n.e.=not evaluated.
*Only data obtained from FoxP3 immunostaining quantification were used in the present analysis.
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484features. FoxP3 staining was found in both tumor cells and
tumor-infiltrating lymphocytes (Figure 1). To quantify the
FoxP3 staining, a tumor cell was considered positive for
FoxP3 when an unambiguous brown staining was observed
in its cytoplasm or nucleus. Each tissue spot was visually
evaluated to estimate the percentage of positive tumor cells
and the intensity of the staining. The percentage of positive
cells was classified as one of the following: 0=no positive
cells; 1=up to 10% positive cells; 2=10 to 30% positive cells;
and 3=more than 30% positive cells. For statistical purposes,
the cases with scores of 0 were defined as negative, and the
cases with scores from 1 to 3 were defined as positive.
The immunohistochemical expression of FoxP3 was
analyzed using the Automated Cellular Imaging System
III (ACIS-III) (DAKO, Carpenteria, CA, USA). Cytoplasmic
and nuclear staining was assessed separately: tissue spots
were digitalized and assigned numerical values propor-
tional to intensity/extension of staining. For the survival
analysis, staining # the median was considered negative,
and staining . the median was considered positive.
The FoxP3
+ lymphocytes were evaluated for each tissue
microarray spot individually by estimating the number of
positive cells per spot, assuming an approximate area of
0.79 mm
2 per cell. To analyze the immunostaining of both the
tumor cells and the tumor-infiltrating lymphocytes, aleatory
spots were obtained from each tissue, and three spots were
assessed to obtain more representative samples from each
lesion. For statistical purposes, the cases weregrouped into the
following categories: 0 (no positive cells), 1+ (up to 10 positive
cells per spot) and 2+ (10 or more positive cells per spot).
Statistical analysis
The statistical analyses were performed using the
Statistical Analysis System for Windows (SAS Institute
Inc., Version 9.1.3, Service Pack 3, 2002-2003, Cary, NC,
USA). The disease-free survival was calculated using
Kaplan-Meier curves with log-rank comparisons. Nonpar-
ametric analyses were performed using the chi-square or
Fisher’s exact test, as indicated. A multivariate logistic
regression model was applied using benignancy/malig-
nancy as the dependent variable and clinical risk factors,
including gender and age, as the explicative variables. The
Mann-Whitney test was used to compare the continuous or
arranged measurements of two groups with variables that
did not present a Gaussian distribution, and the Kruskal-
Wallis test was used to compare three or more such groups.
The immune cell and tumor markers were assessed for their
sensitivity, specificity and predictive value in malignancy.
Quantitative data were expressed as the mean ¡ standard
deviation. The accuracy of the quantification of the FoxP3
expression in predicting malignancy was evaluated with a
receiver operating characteristic (ROC) curve analysis that
was based on predicted probabilities from the logistic
regression models. All the tests were conducted at a 0.05
significance level.
Ethics
This study was approved by the Research Ethics
Committee of the A.C. Camargo Cancer Hospital, Sa ˜o
Paulo, Brazil.
RESULTS
As expected, the majority (83.6%) of the patients were
females. Individuals with benign (49.2¡15.1 years old) and
malignant (43.6¡15.9 years old) thyroid lesions presented
at similar ages at diagnosis. The differentiated thyroid
carcinoma patients were classified, according to the patho-
logic Tumor Node Metastasis staging system (22), as stage I
(157 cases), II (28 cases), III (40 cases) or IV (41 cases). Ninety
tumors were classified as encapsulated, and 176 were
classified as nonencapsulated; 118 were multifocal tumors,
and 148 were unifocal tumors. Additionally, 108 patients
presented with extrathyroidal invasion, whereas 158 did
not. Fifty-five patients (20.6%, including 10 who died from
the disease) experienced recurrences, whereas 211 pro-
gressed free of disease (79.4%).
Semiquantitative analysis of FoxP3 in tumor cells
Four of the five normal thyroid tissues tested negative for
FoxP3 expression, whereas up to 10% of the thyroid cells in
the remaining tissue were negative. Eighty-one of the 114
(71.0%) cases of benign lesions, and 244 of the 266 (91.9%)
malignant cases were FoxP3 positive (p,0.0001). Twenty-
two malignant cases were negative for FoxP3 staining.
Fourteen of the 244 FoxP3
+ malignant cases were scored as
class 1, 11 were scored as class 2 and 219 were scored as
class 3. FoxP3 positivity was more frequent among women
(95.1%) than men (79.4%, p=0.0063). There was no associa-
tion between FoxP3 status and clinical or pathological
features of tumor aggressiveness or long-term patient
outcome.
Quantitative analysis of FoxP3 in tumor cells
A close relationship was found between the results of the
semiquantitative and quantitative analyses of both the cyto-
plasmic (p,0.0001) and nuclear FoxP3 staining (p,0.0001);
however, the numerical values were not distributed according
Figure 1 - Different levels of FoxP3 expression in various thyroid
tissues and lesions. (A) Normal thyroid tissues showed the lowest
FoxP3 staining. (B) Goiter lesions presented with intermediate
FoxP3 immunostaining. In contrast to the normal thyroid, the
goiter cells exhibited increased cytoplasmic and nuclear staining.
(C) Follicular adenoma cells demonstrated pronounced cytoplas-
mic and nuclear FoxP3 immunostaining. (D) Papillary thyroid
carcinomas showed strong FoxP3 expression. In particular,
increased cytoplasmic expression is evident. (E) Follicular thyroid
carcinoma tissues showed faint immunostaining. (F) A papillary
thyroid carcinoma with FoxP3
+ tumor cells and FoxP3
+ lympho-
cytes. The white arrows show regulatory T lymphocytes infiltrat-
ing the malignant tissue. The black arrows show papillary thyroid
carcinoma cells with both cytoplasmic and nuclear FoxP3
staining. Magnification=400x.
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485to a Gaussian curve. We found no significant differences
between the cytoplasmic FoxP3 staining levels of the female
(52.3¡37.4) and male (41.6¡40.5, p=0.0641) differentiated
thyroid carcinoma patients. The cytoplasmic FoxP3 levels were
inversely correlated with the patient’s age at the of the
differentiated thyroid carcinoma diagnosis (Spearman r=
-0.2913, p=0.0001). The Kruskal-Wallis test showed distinct
patterns of FoxP3 expression among the different types of
lesions (p,0.0001), with the malignant lesions staining more
intensely (48.1¡36.2) than the benign ones (31.9¡25.8,
p=0.0005) (Figure 2). The normal thyroid tissues exhibited
the lowest cytoplasmic staining (10.9¡4.8). The classic
papillary thyroid carcinomas received higher staining scores
(55.8¡38.6) than goiters (22.8¡19.6, p,0.0001) and follicular
carcinomas (32.5¡18.9, p=0.0143). A multivariate logistic
regression model indicated that cytoplasmic FoxP3 expression
may be an independent risk factor for malignancy in the
diagnosis of thyroid nodules, albeit with a relatively low
sensitivity and specificity (Table 1). The differentiated thyroid
carcinoma tumors with concurrent chronic lymphocytic
thyroiditis exhibited higher cytoplasmic FoxP3 expression
(67.6¡42.8) when compared with those with no concurrent
chronic lymphocytic thyroiditis (46.1 ¡ 35.6, p=0.0043).
The nuclear FoxP3 staining was also more intense in
younger patients (Spearman r=-0.16479, p=0.01562) but
was similar between different types of lesions (p=0.5622).
Aggressive tumors presenting with metastasis at diagnosis
had stronger nuclear FoxP3 staining (78.1¡24.6) than the
less aggressive lesions (63.9¡27.6, p=0.0011). Spearman’s
log-rank test failed to confirm cytoplasmic (p=0.72045) or
nuclear (p=0.65969) FoxP3 immunostaining as a prognostic
marker.
FoxP3
+ lymphocytic infiltration
No normal thyroid, goiter, follicular adenoma, or follicular
carcinoma cases and only 14.5% of the papillary thyroid
carcinoma cases presented with FoxP3
+ lymphocytes.
However, FoxP3 immunostaining again did not prove suffi-
ciently sensitive to be useful as a diagnostic test (Table 1).
FoxP3
+ l y m p h o c y t e sw e r em o r ec o m m o ni nd i f f e r e n t i a t e d
thyroid carcinomas smaller than 2 cm (p=0.0078), lacking
extrathyroidal invasion (p=0.0122) and accompanied by
chronic lymphocytic thyroiditis (p,0.0001). Tumors with
FoxP3
+ lymphocytic infiltration also exhibited higher cytoplas-
mic FoxP3 expression (76.8¡43.1) than did those without such
infiltration (45.3¡33.5, p=0.0011). However, the nuclear FoxP3
staining was similar among the cases with and without FoxP3
+
lymphocytic infiltration (p=0.95886).
The log-rank test failed to validate FoxP3
+ lymphocytic
infiltration as a prognostic marker. Likewise, a Cox
regression model failed to confirm the reliability of
cytoplasmic FoxP3 staining, nuclear FoxP3 staining and
FoxP3
+ lymphocytic infiltration as independent prognostic
markers. Patients with concurrent chronic lymphocytic
thyroiditis generated a distinct immune response compared
with those without a background of autoimmune disorders.
A multivariate analysis that considered chronic lymphocytic
thyroiditis and FoxP3
+ lymphocytic infiltration as indepen-
dent variables confirmed that the absence of FoxP3
+
lymphocytic infiltration was an independent risk factor for
extrathyroidal invasion (p=0.0048).
DISCUSSION
We found that FoxP3 is expressed not only in differ-
entiated thyroid carcinoma-infiltrating lymphocytes but
also in both the cytoplasm and the nuclei of follicular cells.
Our data demonstrated that FoxP3 nuclear expression is
related to the aggressiveness of differentiated thyroid
carcinomas. In addition, FoxP3
+ lymphocytic infiltration
was more frequent in tumors smaller than 2 cm, lacking
extrathyroidal invasion, and accompanied by chronic
lymphocytic thyroiditis.
FoxP3 expression was initially thought to be restricted to
hematopoietic cells and tissues; however, recent findings
have suggested that other tissues and cell lines are able to
express FoxP3 (5,23-25). The roles of Tregs in different
tumors remain under dispute. There is evidence that the
FOXP3 gene plays a critical role in suppressing pathological
transformation in the prostate (26). However, among
different prostate samples, we found FoxP3 to be more
frequently expressed in tumor cells than in benign nodules,
which suggests that the protein may exert different effects in
different types of tumors. In fact, FoxP3 expression was
shown to progressively decrease as normal cells transform
into prostatic intraepithelial neoplasias (PINs) and prostate
cancer cells, which implies widespread downregulation that
may have occurred at an early stage in prostate cancer
development. Conversely, we found the FoxP3 protein to be
more highly expressed in carcinomas than in nodular
goiters and follicular adenomas.
We found higher cytoplasmic but not nuclear FoxP3
immunostaining in malignant lesions compared with
benign nodules, which suggests that the cytoplasmic
localization of FoxP3 may be a result of the high mutation
rate characteristic of malignant transformation. In fact, the
cytoplasmic (rather than nuclear) localization of FoxP3 has
been considered a consequence of somatic mutations. The
FoxP3 molecule contains a forkhead (FKH)/winged-helix
domain that includes a putative nuclear localization signal.
Mutations in this domain and other transcriptional or
Figure 2 - Cytoplasmic FoxP3 immunostaining in different thyroid
tissues. This boxplot of the immunohistochemical quantification
data provides evidence of progressive FoxP3 staining in different
stages of tumor evolution. Computer-generated numerical values
that represent the intensity and extent of the brown (FoxP3)
staining are plotted on the y-axis. Abbreviations: NT=normal
thyroid; G=goiter; FA=follicular adenoma; FVPTC=follicular
variant of papillary thyroid carcinoma; CPTC=classic papillary
thyroid carcinoma; FC=follicular carcinoma.
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486post-transcriptional modifications could generate the cyto-
plasmic localization of FoxP3 in cancer cells (27-29).
Although FoxP3 expression has also been linked to
tumor aggressiveness, the mechanisms of this protein’s
function and the clinical implications of this association
remain unclear. Ban et al. reported a significant association
between FOXP3 polymorphisms and susceptibility to
autoimmune thyroid disease in Caucasian patients (30).
This finding suggests that FoxP3 may be engaged in the
regulation of the immune response against thyroid tissue.
However, the specific function of FoxP3 in differentiated
thyroid carcinomas remains unclear. In addition to provok-
ing a molecular mimicry that enables immune evasion (24),
FoxP3 may modulate the patterns of molecular expression
in tumor cells, thus favoring an aggressive phenotype (23).
However, the relationship between FoxP3 expression and
patient prognosis is a matter of debate. In studying HER2-
overexpressing breast carcinomas, Ladoire et al. found that
FoxP3 expression was an independent prognostic factor for
increases in both relapse-free and overall survival (27). On
the contrary, Merlo et al. found that the expression of
FoxP3 in tumors was inversely associated with patient
survival(23). These authors also reported a significant
association between FoxP3 expression and lymph node
metastasis, suggesting that FoxP3 expression indicated a
worse prognosis (23).
Here, we demonstrated higher nuclear, but not cytoplas-
mic, FoxP3 immunostaining in the more aggressive differ-
entiated thyroid carcinomas presenting with metastasis at
diagnosis. The inverse correlations between both cytoplas-
mic and nuclear FoxP3 levels and age at diagnosis appear to
reinforce the finding that FoxP3 expression may be
correlated with a worse patient prognosis. However, the
log-rank analysis failed to validate FoxP3 as a reliable
prognostic marker, supporting the current belief that
appropriate management is the most important prognostic
factor in differentiated thyroid carcinoma patients. Another
noteworthy finding was the correlation between FoxP3
expression and patient age. In fact, although children and
adolescents tend to present with higher-stage disease and a
greater likelihood of locoregional and distant metastasis,
they generally exhibit excellent survival rates (31). In
contrast, older patients experience an increased mortality
rate in parallel with the occurrence of metastasis (32,33). The
intriguing possibility of an association between the inverse
correlation between FoxP3 and age revealed in the present
work and the clinical behavior of differentiated thyroid
carcinoma deserves further study.
We found FoxP3
+ lymphocytic infiltration to be associated
with the absence of extrathyroidal invasion, a small tumor
size and the presence of concurrent chronic lymphocytic
thyroiditis. Conversely, studying only 10 papillary thyroid
carcinoma cases, French et al. found that regulatory T cell
infiltration was closely associated with the presence of
lymph node metastasis (19). It is difficult to compare our
data on 253 papillary thyroid carcinomas with those
obtained by these authors, especially because different
methodologies were used. Furthermore, French et al. did
not investigate FoxP3 expression in tumor cells.
In conclusion, we demonstrated FoxP3 expression in
differentiated thyroid carcinoma cells and found evidence
that this expression may exert an important influence on
tumor aggressiveness, especially in cases with strong
nuclear staining. Larger series of patients are warranted to
confirm the clinical utility of FoxP3 staining or Treg
infiltration.
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